|
FY2013
12 months to Dec 31, 2013
|
FY2012
12 months to Dec 31, 2012
|
|
|---|---|---|
| Cash flows used in operating activities: | ||
| Net loss | ||
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Stock-based compensation expense | ||
| Amortization of note discount and note issuance costs | ||
| Depreciation expense | ||
| Change in fair value of embedded conversion derivative | ||
| Gain on sale of discontinued operations | ||
| Depreciation and amortization expense | ||
| Loss on extinguishment of notes | ||
| Net realized gains on sales of available-for-sale securities | ||
| Other | ||
| Deferred rent | ||
| Changes in operating assets and liabilities: | ||
| Accounts receivable, net | ||
| Inventories | ||
| Prepaid expenses | ||
| Other assets | ||
| Accounts payable and accrued compensation | ||
| Other accrued liabilities | ||
| Net cash used in operating activities | ||
| Cash flows from investing activities: | ||
| Proceeds from the divestiture of Actimmune | ||
| Purchases of property and equipment | ||
| Purchases of available-for-sale securities | ||
| Maturities of available-for-sale securities | ||
| Sales of available-for-sale securities | ||
| Net cash (used in) provided by investing activities | ||
| Cash flows from financing activities: | ||
| Proceeds from issuance of common stock in a public offering, net of issuance costs | ||
| Proceeds from convertible senior notes, net of issuance costs | ||
| Repurchase of convertible senior notes | ||
| Proceeds from issuance of common stock under employee stock benefit plans | ||
| Net cash provided by financing activities | ||
| Net increase (decrease) in cash and cash equivalents | ||
| Cash and cash equivalents at beginning of period | ||
| Cash and cash equivalents at end of period | ||
| Supplemental disclosure of cash flow information: | ||
| Interest paid in cash | ||
| Non-cash financing activities: | ||
| Reclassification of derivative liability to stockholders' equity |
Loading...
